Clinical Trial

A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated April 8, 2025 (before its estimated May 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a phase 3, multi-center, randomized, placebo-controlled, double-blind, parallel-group study with an equal randomization among the Hemay005 high dose, lower dose and placebo treatment groups. After subject randomization, each subject will enter an core-treatment Phase for 12 weeks following an extended-treatment phase for another 40 weeks and a follow up phase for 4weeks.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-11-17; most recent amendment 2025-04-06.
Trial Details
NCT Number NCT06145893
Lead Sponsor Ganzhou Hemay Pharmaceutical Co., Ltd
Conditions Behçet's Disease
Enrollment 162 participants
Start Date 2023-11-13
Primary Completion 2026-05-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-08